Trial Profile

A pivotal trial assessing BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elebsiran (Primary) ; VBI 2601 (Primary)
Indications Hepatitis B
Focus Registrational; Therapeutic Use

Most Recent Events

19 Mar 2026 According to a Brii Biosciences media release, the Company has engaged with the CDE of NMPA to discuss potential Phase 3 study designs and primary endpoints in the HBV Program. Results from the ENRICH and ENHANCE studies are expected to inform future registrational development decisions.
25 Mar 2022 New trial record
22 Mar 2022 According to a Brii Biosciences media release, if results of phase 2 combination study are positive the company plans to submit an Investigational New Drug Application (IND) application to China Center for Drug Evaluation (CDE) to initiate this pivotal study in 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com